

## Global Human Growth Hormones Deficiency (GHD) Drugs Market 2018 Size, Share, Growth, Trends, Analysis and Forecast -2023

WiseGuyReports.com adds "Human Growth Hormones Deficiency (GHD) Drugs Market 2018 Global Analysis Research Report Forecasting to 2025" reports to its database.

PUNE, INDIA, April 25, 2018 /EINPresswire.com/ -- <u>Human Growth Hormones Deficiency (GHD)</u> <u>Drugs Market</u>:

## **Executive Summary**

The report presents the market potential of four major pipeline drugs (TransCon-hGH, Somapacitan, Somavaratan, Somatrogonmeant) for the treatment of human Growth Hormone Deficiency (GHD). These four drugs that fall in the various categories of paediatrics and adults by end user have been recognized as being clinically effective in human Growth Hormone Deficiency treatment. Expected to be launched in the market within the next 4-5 years, these four potential drugs are likely to bring about major changes in the way Growth Hormone Deficiency is treated globally.

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market by assessing the potential of the four drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the four drugs, the product profile, description and regulatory phase of each of the four drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the four drugs to present the current perspective.

The report titled "Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2023" also analyzes the overall sizing, growth and forecast of Growth Hormone Deficiency Drugs Market for the global market.

Over the recent years, the human Growth Hormone Deficiency Drugs market is growing rapidly due to rising prevalence of patients with Growth Hormone Deficiency (GHD) around the world. Globally, the growth of human Growth Hormone Deficiency Drugs market is driven by increased penetration of drugs by market players coupled with introduction of new drugs with improved patient compliance.

The global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market is projected to display a robust growth during 2018 – 2023, chiefly driven by low efficacy and poor dosing schedules of present drugs and improved safety and efficacy of investigational drugs. The report has covered and analysed the present human Growth Hormone Deficiency (GHD) drugs in the market and has also analysed potential of four major pipeline drugs. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation.

Request Sample Report @ <a href="https://www.wiseguyreports.com/sample-request/3136550-global-human-growth-hormones-deficiency-ghd-drugs-market">https://www.wiseguyreports.com/sample-request/3136550-global-human-growth-hormones-deficiency-ghd-drugs-market</a>

Scope of the Report

Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Assessment – TransCon-hGH, Somapacitan, Somavaratan, Somatrogon (Forecast Period: 2020-2023)

- Market Potential
- Clinical Trials
- Product Description
- Regulatory Phases
- 7Ps Analysis

Global human Growth Hormone Deficiency (GHD) Pipeline Drugs Market – Sizing and Growth

Actual Period: 2013-2017

Forecast Period: 2018-2023

Regional Analysis - Human Growth Hormone Deficiency (GHD) Pipeline Drugs Market – Sizing and Growth: North America, Europe, Rest of the World

Actual Period: 2013-2017

Forecast Period: 2018-2023

Country Analysis - Human Growth Hormone Deficiency (GHD) Pipeline Drugs Market – Sizing and Growth: US, UK, France, Spain, Germany, Japan

Actual Period: 2013-2017

• Forecast Period: 2018-2023

Other Report Highlights

• Company Analysis – Ascendis Pharma A/S, Novo Nordisk A/S, Versartis Inc., Opko Health Inc., Pfizer Inc.

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Content:

1. Research Methodology

- 2. Executive Summary
- 3. Growth Hormone Deficiency Drugs Product An Overview
- 4. Diagnosis of Growth Hormone Deficiency (GHD)
- 5. Treatment of Growth Hormone Deficiency (GHD)
- 6. Global Growth Hormone Drugs Market
- 7. Global Growth Hormone Deficiency Drugs Market
- 8. Global Growth Hormone Deficiency Drugs Market, By End User
- 9. Global Growth Hormone Deficiency Drugs Market: Regional Analysis
- 10. Global Growth Hormone Deficiency Drugs Market: Country Analysis
- 11. human Growth Hormone Deficiency (hGHD) Pipeline Drugs Coverage
- 12. Company Profiles
  - 12.1. Ascendis Pharma A/S
  - 12.2. Novo Nordisk A/S
  - 12.3. Versartis Inc.
  - 12.4. Opko Health, Inc.
  - 12.5. Pfizer Inc List of Figures

## Continuous...

For further information on this report, visit – <a href="https://www.wiseguyreports.com/reports/3136550-global-human-growth-hormones-deficiency-ghd-drugs-market">https://www.wiseguyreports.com/reports/3136550-global-human-growth-hormones-deficiency-ghd-drugs-market</a>

Norah Trent WiseGuy Research Consultants Pvt. Ltd. +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.